Log in

NASDAQ:IDXXIDEXX Laboratories Stock Price, Forecast & News

$338.47
+3.33 (+0.99 %)
(As of 07/14/2020 04:00 PM ET)
Add
Compare
Today's Range
$329.69
Now: $338.47
$339.07
50-Day Range
$290.84
MA: $318.80
$339.47
52-Week Range
$168.65
Now: $338.47
$345.40
Volume357,100 shs
Average Volume621,213 shs
Market Capitalization$28.75 billion
P/E Ratio67.69
Dividend YieldN/A
Beta0.81
IDEXX Laboratories, Inc., together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers that are used in the human point-of-care medical diagnostics market. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was founded in 1983 and is headquartered in Westbrook, Maine.
Read More
IDEXX Laboratories logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.4Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.31 out of 5 stars


Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:IDXX
CUSIP45168D10
Phone207-556-0300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.41 billion
Cash Flow$6.02 per share
Book Value$2.07 per share

Profitability

Net Income$427.72 million

Miscellaneous

Employees9,200
Market Cap$28.75 billion
Next Earnings Date8/6/2020 (Estimated)
OptionableOptionable

Receive IDXX News and Ratings via Email

Sign-up to receive the latest news and ratings for IDXX and its competitors with MarketBeat's FREE daily newsletter.

IDEXX Laboratories (NASDAQ:IDXX) Frequently Asked Questions

How has IDEXX Laboratories' stock been impacted by COVID-19 (Coronavirus)?

IDEXX Laboratories' stock was trading at $245.58 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, IDXX shares have increased by 37.8% and is now trading at $338.47. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of IDEXX Laboratories?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for IDEXX Laboratories.

When is IDEXX Laboratories' next earnings date?

IDEXX Laboratories is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for IDEXX Laboratories.

How were IDEXX Laboratories' earnings last quarter?

IDEXX Laboratories, Inc. (NASDAQ:IDXX) announced its quarterly earnings results on Thursday, April, 30th. The company reported $1.29 earnings per share for the quarter, topping the Zacks' consensus estimate of $1.20 by $0.09. The business had revenue of $626.30 million for the quarter, compared to the consensus estimate of $616.87 million. IDEXX Laboratories had a net margin of 17.78% and a return on equity of 264.71%. The company's quarterly revenue was up 8.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.17 earnings per share. View IDEXX Laboratories' earnings history.

How will IDEXX Laboratories' stock buyback program work?

IDEXX Laboratories announced that its Board of Directors has initiated a stock repurchase program on Wednesday, February 12th 2020, which allows the company to buyback 5,000,000 outstanding shares, according to EventVestor. This buyback authorization allows the company to purchase shares of its stock through open market purchases. Shares buyback programs are usually a sign that the company's leadership believes its stock is undervalued.

What price target have analysts set for IDXX?

5 brokers have issued 1 year target prices for IDEXX Laboratories' shares. Their forecasts range from $277.00 to $310.00. On average, they expect IDEXX Laboratories' share price to reach $289.00 in the next twelve months. This suggests that the stock has a possible downside of 14.6%. View analysts' price targets for IDEXX Laboratories.

What are Wall Street analysts saying about IDEXX Laboratories stock?

Here are some recent quotes from research analysts about IDEXX Laboratories stock:
  • 1. According to Zacks Investment Research, "IDEXX exited the fourth quarter on a strong note, with better-than-expected numbers. The solid organic revenue growth during the quarter, driven by strong sales at the CAG business, is encouraging. The company witnessed sturdy gains from CAG Diagnostics in the quarter. It also saw strong performances by IDEXX VetLab consumables, reference laboratory diagnostic and consulting as well as moderately robust growth in rapid assay product revenues globally. The strong performance can also be attributed to impressive growth in the LPD and water segments. The global adoption of its latest products and services, including the rapid expansion of Catalyst installed base, is another contributing factor. Over the past three months, IDEXX has been outperforming its industry. However, operating margin contracted during the quarter." (2/4/2020)
  • 2. Canaccord Genuity analysts commented, "We think IDXX is likely due for a new product launch around 2020 or so, but whether they announce it at the Analyst Day, or VMX remains to be seen. We reiterate our Buy on IDXX and raise our PT to $285, as we roll forward to our new 2021 estimates. Q2 beat on the bottom, delivered small miss on the top. Q2 Adj. EPS of $1.43 (+16% rep, +19% FXN) beat our $1.35/Street’s $1.37 and OM of 26.5% (+140bps Y/Y) beat our 25.4%E, as G&A came in $5M below us (disciplined expense management, low benefit costs and LPD cost controls). Q2 revs of $620M (+7% rep., +9% FXN) missed our $625M/Street’s $627M (see shortfall rationale below). GMs of 57.7% grew 50bps Y/Y and matched us (helped by 2-3% price increases, and mix benefits). Q2 rev. shortfall." (8/2/2019)

Has IDEXX Laboratories been receiving favorable news coverage?

Headlines about IDXX stock have trended somewhat positive on Wednesday, according to InfoTrie Sentiment. The research firm scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. IDEXX Laboratories earned a media sentiment score of 2.0 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the next few days. View the latest news about IDEXX Laboratories.

Are investors shorting IDEXX Laboratories?

IDEXX Laboratories saw a decline in short interest during the month of June. As of June 30th, there was short interest totaling 1,880,000 shares, a decline of 8.3% from the June 15th total of 2,050,000 shares. Based on an average trading volume of 609,800 shares, the short-interest ratio is presently 3.1 days. Currently, 2.2% of the company's shares are short sold. View IDEXX Laboratories' Current Options Chain.

Who are some of IDEXX Laboratories' key competitors?

What other stocks do shareholders of IDEXX Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEXX Laboratories investors own include NVIDIA (NVDA), Alibaba Group (BABA), Paypal (PYPL), Netflix (NFLX), Mastercard (MA), Adobe (ADBE), Intuitive Surgical (ISRG), salesforce.com (CRM), Walt Disney (DIS) and Home Depot (HD).

Who are IDEXX Laboratories' key executives?

IDEXX Laboratories' management team includes the following people:
  • Mr. Jonathan W. Ayers, Chairman, CEO & Pres (Age 63)
  • Mr. Brian P. McKeon, CFO, Exec. VP & Treasurer (Age 57)
  • Ms. Jacqueline L. Studer, Corp. VP, Gen. Counsel & Corp. Sec. (Age 60)
  • Mr. Giovani Twigge, Chief HR Officer & Corp. VP (Age 55)
  • Mr. Jay Mazelsky, Exec. VP of Companion Animal Group (Age 58)

What is IDEXX Laboratories' stock symbol?

IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."

Who are IDEXX Laboratories' major shareholders?

IDEXX Laboratories' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Riverbridge Partners LLC (0.14%), Envestnet Asset Management Inc. (0.10%), LGT Capital Partners LTD. (0.08%), Spence Asset Management (0.05%), Woodstock Corp (0.05%) and Capital Investment Services of America Inc. (0.04%). Company insiders that own IDEXX Laboratories stock include Brian P Mckeon, Bruce L Claflin, Giovani Twigge, Jacqueline Studer, James F Polewaczyk, Jay Mazelsky, Jonathan W Ayers, Lawrence D Kingsley, M Anne Szostak, Michael Lane, Rebecca M Henderson and Sophie V Vandebroek. View institutional ownership trends for IDEXX Laboratories.

Which major investors are selling IDEXX Laboratories stock?

IDXX stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, IFM Investors Pty Ltd, Cacti Asset Management LLC, Aries Wealth Management, Robecosam AG, Scout Investments Inc., Woodstock Corp, and Stock Yards Bank & Trust Co.. Company insiders that have sold IDEXX Laboratories company stock in the last year include Giovani Twigge, James F Polewaczyk, Jay Mazelsky, Jonathan W Ayers, M Anne Szostak, Michael Lane, Rebecca M Henderson, and Sophie V Vandebroek. View insider buying and selling activity for IDEXX Laboratories.

Which major investors are buying IDEXX Laboratories stock?

IDXX stock was purchased by a variety of institutional investors in the last quarter, including Capital Investment Services of America Inc., Envestnet Asset Management Inc., Riverbridge Partners LLC, LGT Capital Partners LTD., AdvisorShares Investments LLC, Howard Capital Management Inc., Paragon Advisors LLC, and Forte Capital LLC ADV. Company insiders that have bought IDEXX Laboratories stock in the last two years include Bruce L Claflin, and Lawrence D Kingsley. View insider buying and selling activity for IDEXX Laboratories.

How do I buy shares of IDEXX Laboratories?

Shares of IDXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is IDEXX Laboratories' stock price today?

One share of IDXX stock can currently be purchased for approximately $338.47.

How big of a company is IDEXX Laboratories?

IDEXX Laboratories has a market capitalization of $28.75 billion and generates $2.41 billion in revenue each year. The company earns $427.72 million in net income (profit) each year or $4.89 on an earnings per share basis. IDEXX Laboratories employs 9,200 workers across the globe.

What is IDEXX Laboratories' official website?

The official website for IDEXX Laboratories is www.idexx.com.

How can I contact IDEXX Laboratories?

IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The company can be reached via phone at 207-556-0300 or via email at [email protected]

This page was last updated on 7/15/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.